Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Manal F. Abdelmalek"'
Autor:
Don C. Rockey, Andrew H. Beck, Murray B. Resnick, Nezam H. Afdhal, Michael Christopher Montalto, Oscar Carrasco-Zevallos, Catherine Jia, Zachary Goodman, Harsha Pokkalla, Mitchell L. Shiffman, Zahil Shanis, Ling Han, Jaime Bosch, Manal F. Abdelmalek, Arun J. Sanyal, Quang Huy Le, Chuhan Chung, Robert P. Myers, Ilan Wapinski, Stephen A. Harrison, Dinkar Juyal
Publikováno v:
Bosch, Jaime; Chung, Chuhan; Carrasco-Zevallos, Oscar M; Harrison, Stephen A; Abdelmalek, Manal F; Shiffman, Mitchell L; Rockey, Don C; Shanis, Zahil; Juyal, Dinkar; Pokkalla, Harsha; Le, Quang Huy; Resnick, Murray; Montalto, Michael; Beck, Andrew H; Wapinski, Ilan; Han, Ling; Jia, Catherine; Goodman, Zachary; Afdhal, Nezam; Myers, Robert P; ... (2021). A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis. Hepatology, 74(6), pp. 3146-3160. Wiley 10.1002/hep.32087
BACKGROUND AND AIMS The hepatic venous pressure gradient (HVPG) is the standard for estimating portal pressure but requires expertise for interpretation. We hypothesized that HVPG could be extrapolated from liver histology using a machine learning (M
Autor:
Elizabeth K. Fletcher, Athan Kuliopulos, Nga Nguyen, Srijoy Guha, Andrew Shearer, Daniel H. Cox, James D. Baleja, Ying Wang, Manal F. Abdelmalek, Lidija Covic, Rajashree Rana
Publikováno v:
Molecular Metabolism, Vol 29, Iss, Pp 99-113 (2019)
Molecular Metabolism
Molecular Metabolism
Objective Increases in hepatic and plasma cholesterol occur in patients with nonalcoholic fatty liver disease (NAFLD), although the reason for this is not well understood. We investigated whether Protease-Activated Receptor 2 (PAR2) plays a role in c
Autor:
Cynthia D. Guy, Ying Wang, Anna Mae Diehl, Dana Portenier, Dawn Piercy, Matthew J Crowley, Andrea D. Coviello, Anastasia-Stefania Alexopoulos, Ranjan Sudan, Cynthia A. Moylan, Manal F. Abdelmalek, Keri A. Seymour, Ricardo Henao
Publikováno v:
Hepatology (Baltimore, Md.). 74(3)
BACKGROUND AND AIMS Whether glycemic control, as opposed to diabetes status, is associated with the severity of NAFLD is open for study. We aimed to evaluate whether degree of glycemic control in the years preceding liver biopsy predicts the histolog
Autor:
Manal F. Abdelmalek, Margery A. Connelly, Stephen J. Rossi, Mary E. Rinella, Angelo H. Paredes, Stephen A. Harrison, Lei Ling, James F. Trotter, Mark J. Jaros, Alex M. DePaoli
Publikováno v:
Journal of Hepatology. 70:735-744
NGM282, an engineered analogue of the gut hormone FGF19, improves hepatic steatosis and fibrosis biomarkers in patients with non-alcoholic steatohepatitis (NASH). However, NGM282 increases serum cholesterol levels by inhibiting CYP7A1, which encodes
Autor:
Anna Mae Diehl, Nezam H. Afdhal, Andrew J. Muir, Jaime Bosch, G. Mani Subramanian, Zachary Goodman, Raul Aguilar Schall, Arun J. Sanyal, Stephen A. Harrison, Stephen H. Caldwell, B. Mccolgan, Maria Stepanova, Manal F. Abdelmalek, Robert P. Myers, Vlad Ratziu, Zobair M. Younossi, Mitchell L. Shiffman
Publikováno v:
Journal of Hepatology. 69:1365-1370
Although patients with cryptogenic cirrhosis have historically been considered as having "burnt-out" non-alcoholic steatohepatitis (NASH), some controversy remains. The aim of this study was to compare outcomes of patients with cryptogenic cirrhosis
Autor:
B. Mccolgan, Eric Lawitz, Anna Mae Diehl, Catherine Jia, Manal F. Abdelmalek, Jaime Bosch, Zobair M. Younossi, G. Mani Subramanian, Mitchell L. Shiffman, John G. McHutchison, Reem Ghalib, Nezam H. Afdhal, Don C. Rockey, Andrew J. Muir, Raul Aguilar Schall, Vlad Ratziu, Zachary Goodman, Stephen H. Caldwell, Arun J. Sanyal, Stephen A. Harrison, Robert P. Myers
Publikováno v:
Gastroenterology. 155:1140-1153
Background & Aims Lysyl oxidase-like 2 contributes to fibrogenesis by catalyzing cross-linkage of collagen. We evaluated the safety and efficacy of simtuzumab, a monoclonal antibody against lysyl oxidase-like 2, in two phase 2b trials of patients wit
Autor:
Kris V. Kowdley, Stephen A. Harrison, Manal F. Abdelmalek, Arun J. Sanyal, Zachary Goodman, Guruprasad P. Aithal, Star Seyedkazemi, Vincent Wai-Sun Wong, Rohit Loomba, Vlad Ratziu, Frank Tacke, Sven Francque, Laurent Fischer
Publikováno v:
Hepatology
Hepatology, Wiley-Blackwell, 2020, 72 (3), pp.892-905. ⟨10.1002/hep.31108⟩
Hepatology, Wiley-Blackwell, 2020, 72 (3), pp.892-905. ⟨10.1002/hep.31108⟩
International audience; Background and aims: Cenicriviroc (CVC) is a C-C chemokine receptors type 2 and 5 dual antagonist under evaluation for treating liver fibrosis in adults with nonalcoholic steatohepatitis (NASH). Year 1 primary analysis of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a6a62c5ef92690b2ab38f7860b50fdc
https://hal.sorbonne-universite.fr/hal-03213544
https://hal.sorbonne-universite.fr/hal-03213544
Autor:
Ying Wang, Anna Mae Diehl, Ricardo Henao, Manal F. Abdelmalek, Keri A. Seymour, Ranjan Sudan, Matthew J Crowley, Cynthia D. Guy, Anastasia-Stefania Alexopoulos, Dana Portenier, Andrea D. Coviello
Publikováno v:
Diabetes. 69
T2DM increases risk for advanced fibrosis in NAFLD, however little is known about the impact of glycemic control on fibrosis severity. Objective: To assess whether glycemic control is associated with severity of fibrosis in NAFLD. Methods: We utilize
Autor:
Francesco Negro, Keith D. Lindor, Kris V. Kowdley, Michael Charlton, Manal F. Abdelmalek, Stephen H. Caldwell, Elisabetta Bugianesi, Quentin M. Anstee, V. Ratziu, Zobair M. Younossi, Brent A. Neuschwander-Tetri, Stephen A. Harrison, Rohit Loomba, Jacob George, Scott L. Friedman, Kathleen E. Corey, Philippe Mathurin, Joel E. Lavine, A. Sanyal, Zachary Goodman, Lawrence Serfaty, Giulio Marchesini, Mary E. Rinella, N. Chalasani
Publikováno v:
Hepatology (Baltimore, Md.), vol 68, iss 1
Nonalcoholic fatty liver disease (NAFLD) is a spectrum comprised of isolated steatosis, nonalcoholic steatohepatitis (NASH), advanced fibrosis, and cirrhosis. The majority of NAFLD subjects do not have NASH and do not carry a significant risk for liv
Autor:
Laura A. Wilson, James Tonascia, Jeanne M. Clark, Srinivasan Dasarathy, Brent A. Neuschwander-Tetri, David E. Kleiner, Manal F. Abdelmalek, Bilal Hameed, Oscar W. Cummings, Arun J. Sanyal, Rohit Loomba, Kris V. Kowdley, Samer Gawrieh, Edward Doo, Naga Chalasani
Publikováno v:
Am J Gastroenterol
OBJECTIVES Patients with nonalcoholic fatty liver disease (NAFLD) and normal aminotransferase levels may have advanced liver histology. We conducted a study to characterize the prevalence of and factors associated with advanced liver histology in pat